Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Net Cash Flow (2020 - 2022)

Atea Pharmaceuticals (AVIR) has 3 years of Net Cash Flow data on record, last reported at $11.9 million in Q4 2022.

  • For Q4 2022, Net Cash Flow rose 115.86% year-over-year to $11.9 million; the TTM value through Dec 2022 reached -$576.0 million, down 573.39%, while the annual FY2025 figure was $31.0 million, 139.2% up from the prior year.
  • Net Cash Flow reached $11.9 million in Q4 2022 per AVIR's latest filing, up from -$508.1 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $744.7 million in Q4 2020 and bottomed at -$508.1 million in Q3 2022.
  • Average Net Cash Flow over 3 years is $13.9 million, with a median of -$13.4 million recorded in 2020.
  • Peak YoY movement for Net Cash Flow: surged 324.79% in 2021, then tumbled 2271.42% in 2022.
  • A 3-year view of Net Cash Flow shows it stood at $744.7 million in 2020, then crashed by 110.11% to -$75.3 million in 2021, then surged by 115.86% to $11.9 million in 2022.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were $11.9 million in Q4 2022, -$508.1 million in Q3 2022, and -$21.1 million in Q2 2022.